36 results about "Isozyme" patented technology

The invention belongs to the technical field of nuclear medicine, and relates to a CAIX-targeted cyclic peptide and a preparation method and application thereof, the CAIX-targeted cyclic peptide structure is shown as a formula 1, Linker is a cyclization connexon, and Chenator is a nuclide chelating group. The CAIX-targeted cyclic peptide provided by the invention has high affinity with CAIX, and has low affinity with isoenzyme CAII of CAIX, so that the CAIX-targeted cyclic peptide has high selective affinity with CAIX; the nuclide-labeled radioactive probe has high labeling rate and excellent in-vitro stability, has excellent pharmacokinetic characteristics in tumor-bearing model mice of human renal clear cell carcinoma, and has extremely high tumor uptake, tumor-muscle ratio and tumor-kidney ratio which can meet diagnosis requirements; due to the long-time retention characteristic in tumors, the polymer has a relatively high tumor treatment application value.

The application discloses a high-activity UGT1A1 enzyme based on tree shrew and a feed composition for enhancing alcohol metabolism. The catalytic efficiency of the recombinant tree shrew UGT1A1 enzyme on ethanol is significantly higher than that of human isozyme. The core of the application is to provide a complex feed system containing the enzyme, which solves the key bottleneck of poor stability and low delivery efficiency of exogenous enzymes in application through the synergistic effect of enzyme stabilizers, cell penetration enhancers, enteric coatings and coenzyme supply agents. Animal experiments show that the composition can safely and effectively accelerate in vivo alcohol elimination and reduce blood ethanol concentration, and can be used for developing alcoholism products, acute alcoholism treatment drugs and alcoholic liver disease prevention preparations.

The invention discloses application of eupatolide in preparation of a medicine for preventing and treating inflammatory bowel disease, application of eupatolide in preparation of a medicine for preventing and treating inflammatory bowel disease and application of a medicine preparation containing eupatolide in preparation of a medicine for preventing and treating inflammatory bowel disease, and researches that eupatolide (EPT) can be used for preparing the medicine for preventing and treating inflammatory bowel disease through targeting pyruvate kinase isoenzyme 2 (PKM2, Gene ID: 5135). The inflammatory response, glycolysis metabolism and mitochondrial homeostasis are synergistically regulated and controlled, so that the inhibition effect on the inflammatory bowel disease is exerted. Meanwhile, EPT has the advantages of being low in dosage, feasible in oral administration, free of obvious toxic and side effects and the like, and a solid experimental basis is provided for further developing EPT into candidate drugs for preventing and treating inflammatory bowel diseases.

The present invention relates to protein ligands for carbonic anhydrase IX (CAIX) as a biomedically relevant target. In particular, highly specific ligands can interact exclusively with an antigen, i.e., CAIX, expressed on the surface of tumor cells, sparing healthy target-expressing organs, thereby enabling efficient in vivo drug delivery applications. Ligands can exhibit particularly low dissociation constants and / or enzyme isoform specificity, making them suitable for targeted delivery of payloads, such as therapeutic and / or diagnostic agents, to sites affected by or at risk of diseases or disorders characterized by CAIX expression.

The present invention discloses the use of a traditional Chinese medicine composition in the preparation of a drug for preventing or treating diabetic cardiomyopathy. The traditional Chinese medicine composition of the present invention is composed of notopterygium root, angelica dahurica, Poria cocos, saposhnikovia root, schizonepeta tenuifolia, ligusticum wallichii, chuanxiong rhizome, platycodon grandiflorum, bupleurum root, peucedanum chinense, fructus aurantii, and liquorice. Pharmacodynamic experimental results show that the traditional Chinese medicine composition of the present invention can reduce serum creatine kinase isoenzyme (CK-MB) and lactate dehydrogenase (LDH) levels, and can significantly improve diabetic myocardial cell damage; reduce cardiac index, improve myocardial hypertrophy and left ventricular remodeling, and has the effect of preventing and treating diabetic cardiomyopathy.

The invention relates to the field of antifungal biosurfactant molecules of bacterial origin. More particularly, the invention concerns novel strains of Bacillus subtilis producing new isoforms of mycosubtilin, their preparation process, and compositions containing them. These new isoforms of mycosubtilin exhibit improved antifungal activity and reduced cytotoxic properties compared to prior art mycosubtilins.

The invention belongs to the technical field of glutamic acid content detection, and particularly relates to a method for detecting the glutamic acid content based on glutamine synthetase isoenzyme and application of the method. The invention relates to a glutamine synthetase isoenzyme TaGS1; the invention discloses application of glutamine synthetase TaGS1, TaGS2, TaGS2, TaGS2, TaGS2, TaGS2, TaGS2, TaGS2; the amino acid sequence of 3 is as shown in SEQ ID No.1 in the table. The method has the advantages that (1) the TaGS1 is disclosed through a multi-dimensional experiment system; the invention relates to catalytic characteristics and application potential of TaGS1, TaGS2, TaGS2, TaGS2; the temperature adaptability and substrate specificity of the enzyme 1, 2, 3 show high consistency with that of an HPLC (High Performance Liquid Chromatography) detection method in a cross validation experiment; (2) the method for detecting the content of glutamic acid is obviously superior to other glutamate dehydrogenase detection methods, for example, GDH is often interfered by alpha-ketoglutaric acid; and (3) the method for detecting the content of glutamic acid does not need complex sample pretreatment or expensive instruments, the single detection cost is about 10% of that of an HPLC method, and the flux is high.

The disclosure provides methods for detecting and diagnosing diseases and conditions associated with defects in cardiolipin remodeling. In some embodiments, the present technology relates to methods for detecting the presence or amount of cardiolipin isoforms and / or the presence or amount of enzymes involved in cardiolipin remodeling.

Well-defined, xeno-free culture media which comprise a TGF-beta isoform or the chimera formed between IL6 and the soluble IL6 receptor (IL6RIL6), which are capable of maintaining stem cells, and particularly, human embryonic stem cells, in an undifferentiated state are provided. Also provided are cell cultures comprising the culture media and the stem cells and methods of expanding and deriving embryonic stem cells in such well-defined, xeno-free culture media. In addition, the present invention provides methods of differentiating ESCs or EBs formed therefrom for the generation of lineage specific cells.

The present disclosure provides a pharmaceutical composition comprising a NUPR1 isoform A inhibitor as an active ingredient. Pharmaceutical compositions comprising an NUPR1 isoform A inhibitor may be used in methods of preventing or treating cancer, in methods of diagnosing or predicting prognosis of cancer comprising an agent for measuring an expression or activity level of a NUPR1 isoform A, in a kit for diagnosing or predicting prognosis of cancer comprising the composition, methods for screening a substance for inhibiting cancer cell proliferation or metastasis, methods for providing information for cancer cell proliferation or metastasis, in food compositions for preventing or improving cancer comprising a NUPR1 isoform A inhibitor as an active ingredient, and in feed compositions for preventing or improving cancer comprising a NUPR1 isoform A inhibitor as an active ingredient.

Compounds and methods are provided for inhibiting an aldehyde dehydrogenase (ALDH). Methods of treating cancer are also provided. The ALDH-inhibitor can be a compound that is based on a cyclic guanidine, or an imidazolium core. In certain embodiments, the ALDH-inhibitor compound is a substituted cyclic guanidine, or a substituted imidazolium compound. Aspects of the methods include methods of selectively inhibiting a particular ALDH family member. In some cases, the subject compounds are ALDH1B1-selective inhibitors. In some cases, the subject compounds are ALDH1A3-selective inhibitors.

In order to solve the problems of low product yield, low safety, complicated post-treatment, serious environmental pollution and the like in the existing synthesis method, the invention provides a synthesis method of tazobactam diphenylmethyl ester. The synthesis method comprises the following steps: obtaining a chloromethylation product (compound A) from debrominated sulfoxide diphenyl methyl ester under the action of benzoyl chloride and quinoline in one step; carrying out substitution reaction on the compound A and triazole to obtain a compound B; under the catalysis of horseradish peroxidase isoenzyme C, the compound B is efficiently oxidized into tazobactam diphenylmethyl ester by H2O2. According to the method, a traditional chloromethylation product synthesis method (thermal cracking and diazotization reaction) is abandoned, the chloromethylation product can be obtained in one step, no dangerous reaction exists, few byproducts are generated, the yield is high, and atom economy is high (benzoyl chloride and quinoline can be recycled and reused); an enzyme / hydrogen peroxide catalytic system is adopted in the oxidation step, so that the catalytic efficiency is high, the generation of solid wastes is greatly reduced, and the method is green and environment-friendly.

The present disclosure provides compounds of Formula (I) and pharmaceutically acceptable salts thereof, and compounds of Formula (II) and pharmaceutically acceptable salts thereof, which inhibit phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) isoform alpha (PI3Kα). These chemical entities are useful, for example, for treating conditions, diseases, or disorders in which increased (e.g., excessive) PI3Kα activation contributes to the pathology and / or symptoms and / or progression of the condition, disease, or disorder (e.g., cancer) in a subject (e.g., a human). The disclosure also provides compositions containing them, as well as methods of using and making them. TIFF2025535066000159.tif54128

Methods for identifying chronic hydrocephalus include assaying for an amount in a biological sample of one or more biomarkers selected from pyruvate dehydrogenase lipoamide kinase isozyme 4 (PDK4), phosphofructokinase-muscle (PFKM), low density lipoprotein receptor adaptor protein 1 (LDLRAP1), glucagon-like peptide-1 receptor (GLP-1R), hemoglobin subunit alpha 1 (HBA1), hemoglobin subunit alpha 2 (HBA2), heme oxygenase 1 (HMOX1), and combinations thereof. Methods for screening for a compound useful for treating chronic hydrocephalus are also provided and include contacting a cell with an effective amount of a test compound, and then detecting an expression or activity level of one or more of the biomarkers.

The present disclosure relates to the field of molecules of antifungal biosurfactants of bacterial origin. More particularly, the present disclosure relates to new Bacillus Subtilis strains producing new isoforms of mycosubtilins, a preparation method therefor, and compositions containing same. These novel mycosubtilin isoforms exhibit improved antifungal activities and reduced cytotoxic properties compared with mycosubtilins of the prior art.

The present invention provides compounds for the regulation of P-glycoprotein and cytochrome P450 (e.g., CYP3A4 and CYP3A5 isoforms) enzymes, which a) significantly improve the bioavailability of substrates of these enzymes, including anticancer drugs, b) overcome multidrug resistance in tumors, and c) reduce serious side effects while improving the delivery of P-glycoprotein substrates to the brain. [Solution] Compounds of formula (I), as well as their prodrugs and pharmaceutically acceptable salts, are provided. Further disclosure relates to pharmaceutical compositions containing the compounds, methods of use, and methods for preparing them. TIFF2026086798000135.tif39128

Disclosed is use of inhibiting hexokinase isozyme 2 in the treatment of herpes simplex viral keratitis. The present application provides use of an inhibitor of hexokinase isozyme 2 in the preparation of a pharmaceutical composition for treating or preventing herpes simplex viral keratitis in an individual. The present application further provides a pharmaceutical composition for treating or preventing herpes simplex viral keratitis. The present application further provides a method for screening for a drug for treating or preventing herpes simplex viral keratitis. The present application further provides a screening system and a screening device for a drug for treating or preventing herpes simplex viral keratitis. The present application further provides a related computer-readable storage medium.

This invention relates to the field of biotechnology, specifically to the construction and application of a Benzodiacetic tobacco chassis for synthesizing isoflavones. This invention reconstructs the upstream pathway for isoflavone synthesis in Benzodiacetic tobacco, further identifies and screens key rate-limiting enzymes for isoflavone synthesis in Benzodiacetic tobacco, and utilizes 2A peptides to co-express multiple key genes, further introducing flavonoid synthesis transcription factors to construct a Benzodiacetic tobacco chassis for synthesizing isoflavones. This Benzodiacetic tobacco chassis can efficiently synthesize daidzein and genistein. Furthermore, based on the constructed high-yield Benzodiacetic tobacco platform for daidzein and genistein, various isoflavones can be further synthesized, such as daidzein, genistein, puerarin, gentiopicrin, chickpea extract A, and stigmosiderin, paving the way for the industrialization of plant biosynthesis of various bioactive isoflavones and thus possessing broad application prospects.

The application belongs to the technical field of nuclear medicine, and relates to a CAIX-targeting cyclic peptide as well as a preparation method and application thereof. The structure of the CAIX-targeting cyclic peptide is shown as formula 1. The Linker is a ring-forming linker. The Chelator is a radionuclide chelating group. The CAIX-targeting cyclic peptide provided by the application has high affinity with CAIX and low affinity with CAIX isozyme CAII, so that the CAIX-targeting cyclic peptide has high selective affinity with CAIX. The radionuclide-labeled radioactive probe has high labeling rate and excellent in-vitro stability, has excellent pharmacokinetic characteristics in tumor-bearing model mice of human renal clear cell carcinoma, has extremely high tumor uptake, and can meet the diagnosis requirement of tumor muscle ratio and tumor kidney ratio. The long-time retention characteristics of the probe in the tumor also make the probe have high tumor treatment application value.

The invention belongs to the technical field of gene engineering and enzyme engineering, and particularly relates to beta-1, 3-glucanase and application thereof in promoting extraction of intracellular products of yeast. Specifically, the method comprises the following steps: by taking the yarrowia lipolytica as a platform, expressing two beta-1, 3-glucanase isoenzymes Cc betaglI and Cc betaglS from Cellulosimicrobium cellulas in a wild type yarrowia lipolytica strain Po1g, so as to obtain the yarrowia lipolytica strain Po1g, namely the beta-1, 3-glucanase isoenzymes Cc betaglI and Cc betaglS. Researches find that secretory expression of Cc beta glS in yarrowia lipolytica can obviously improve the digestibility of cell walls and promote cell lysis. Further intracellular protein extraction experiments and beta-carotene extraction experiments prove that secretory expression of the beta-1, 3-glucanase Cc betaglS in yarrowia lipolytica can be cracked by yeast cell walls, so that the extraction efficiency of intracellular products is obviously improved, and the method has good practical application value.

The present invention provides a method of preventing or treating atherosclerosis or a symptom thereof comprising administering to a subject in need thereof a specific inhibitor of neuraminidase 1 (neu1); neuraminidase 3 (neu3); or a bispecific inhibitor of neu1 or neu3 of formula I; (I) and a compound of formula I.

This invention provides a CYP716 gene, protein, and applications for catalyzing the oxidation of β-amyrin at the C22α and C28 positions, belonging to the field of biotechnology. The CYP716 gene includes either CYP716BX1 (nucleotide sequence as shown in SEQ ID No. 1) or CYP716BX2 (nucleotide sequence as shown in SEQ ID No. 2). Studies have shown that CYP716BX1 and CYP716BX2 are isoenzymes, both capable of catalyzing the oxidation of β-amyrin at the C22α and C28 positions to 22α-hydroxy-kapogonadiol or 22α-hydroxy-oleanolic acid, and also capable of catalyzing the oxidation of 21β-hydroxy-β-amyrin at the C22α and C28 positions to 21β,22α-dihydroxy-kapogonadiol. This invention can provide key gene elements for the synthetic biology research of cyrimyl alcohol-type triterpenoids.

Embodiments of the invention are directed to new equatorially modified polymer linked multimers of guanosine-3′, 5′-cyclic monophosphate (cGMP) analogues that inhibit the cGMP-signaling system. The invention is also directed to related monomeric compounds, which may serve as monomeric precursors of the multimers, and / or also show itself inhibitory activity and / or impact the inhibitory activity of the related multimers. The invention further relates to the use of such compounds as reagents for signal transduction research and as modulators of cyclic nucleotide-regulated binding proteins and isoenzymes thereof, and as ligands for affinity chromatography, for antibody production or for diagnostic applications, e.g., on chip surfaces.

The present invention relates to a lateral flow device for detecting at least one protein (AAD protein) in a human / patient body fluid sample that results in release in an acute aortic syndrome / acute aortic dissection (AAS / AAD) event, the device comprising a test strip; a sample pad for receiving a bodily fluid sample; a first conjugate pad having a conjugate comprising a protein antibody that binds to the AAD protein; and a first detection line comprising a first conjugate-binding protein to display the presence of an AAD protein in the sample by visible color changes wherein the AAD protein is selected from a set of biomarkers of AAS / AAD, including D-dimer smooth muscle actin myosin isoenzyme CK-MB and a nucleic acid component (DISAMIN). The invention also relates to a method for detecting AAD protein in the blood of a patient by using the lateral flow device, a kit comprising the device and a method for determining the presence of AAD in the body of a patient by using an immunoassay.

The invention belongs to the technical field of biological medicine, and particularly relates to a polypeptide degradation agent for targeted degradation of CD26 as well as a preparation method and application thereof, and the polypeptide degradation agent is obtained by coupling tetrapeptide and lenalidomide; the amino acid sequence of the tetrapeptide is any one of SEQ ID NO. 1 and SEQ ID NO. 2. The polypeptide degradation agent disclosed by the invention can be used for specifically degrading DPP4, namely CD26 in a targeted manner; however, isoenzymes DPP7, DPP8, DPP9 and the like of DPP4 cannot be degraded, and high selectivity of the isoenzymes DPP7, DPP8, DPP9 and the like is embodied. Besides, the polypeptide degradation agent is small in molecular weight, one end of the polypeptide degradation agent is a natural short peptide, the polypeptide degradation agent has good histocompatibility, target protein can be rapidly degraded within 6 hours, and good tissue permeability is embodied.

The present invention relates to a lateral flow device for detecting at least one protein (AAD protein) released during an event leading to acute aortic syndrome / acute aortic dissection (AAS / AAD) in a human / patient body fluid sample. The device comprises a strip, a sample pad for receiving a body fluid sample, a first conjugate pad having a conjugate containing a protein antibody that binds to the AAD protein, and a first detection band containing the first conjugate-binding protein, the presence of the AAD protein in the sample is indicated by a visible color change. Here, the AAD protein is selected from a group of AAS / AAD biomarkers, including D-dimer, smooth muscle actin myosin isozyme, CK-MB, and nucleic acid component (DISAMIN). Furthermore, the present invention also relates in other aspects to a method for detecting the AAD protein in a patient's blood using the lateral flow device according to the present invention, a kit comprising the device, and a method for determining the presence of AAD in a patient using an immunoassay.

This invention relates to a phospholipase D (PLD) gene that can regulate the morphological development of bamboo fungus and its application. The encoding nucleotide sequences of the phospholipase D gene are shown in SEQ ID NO:1 and SEQ ID NO:2, respectively. The protein encoded by SEQ ID NO:1 is the isoenzyme PLD-1, and its amino acid sequence is shown in SEQ ID NO:3; the protein encoded by SEQ ID NO:2 is the isoenzyme PLD-2, and its amino acid sequence is shown in SEQ ID NO:4. The application involves treating bamboo fungus bulbs with a phospholipase D inhibitor, which can inhibit the opening of the bulb cap. The full-length PLD gene for regulating the morphological development of bamboo fungus provided by this invention is mainly used to regulate the morphological development of bamboo fungus through the use of a PLD inhibitor (hexanal). The PLD inhibitor (hexanal) of this invention can effectively inhibit the morphological development of bamboo fungus bulbs after harvest, improve the preservation of bamboo fungus, and reduce transportation losses.

This disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts thereof, that inhibit phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) isoform alpha (PI3Kα) for use in combination with additional therapeutic agents for treating a condition, disease or disorder in which increased (e.g., excessive) PI3Kα activation contributes to the pathology and / or symptoms and / or progression of the condition, disease or disorder (e.g., cancer) in a subject.

The present application belongs to the field of molecular genetics and breeding of large filamentous fungi, and particularly relates to a double-gene knockout engineering strain of Cordyceps militaris CM0207 , a preparation method thereof and application of the double-gene knockout engineering strain in improving the content of cordycepin in Cordyceps militaris C. militaris . The present application provides a double-gene knockout engineering strain of Cordyceps militaris CM0207 , which is obtained by simultaneously or sequentially performing directional inactivation on adenosine deaminase related isozyme genes CCM_02911 (ada02) and CCM_07169 (ada07) of a starting strain of Cordyceps militaris; the engineering strain is Δ ada02 Δ ada07 . The present application also simultaneously provides application of the double-gene knockout engineering strain of Cordyceps militaris CM0207 in the production of cordycepin. The engineering strain obtained by the present application can be used in liquid fermentation production or solid cultivation application for improving the content of cordycepin in Cordyceps militaris.

This disclosure provides methods and compositions for the production of engineered eukaryotic cells wherein the production of both glutaminase isozymes (Gls and Gls2) and asparaginase (Aspg) is reduced such that ammonia production is almost entirely eliminated before stationary phase and substantially decreases it over the course of culture, even when grown in glutamine-containing medium.